Tirzepatide benefits documented in clinical trials extend past body weight to glycemic control, obstructive sleep apnea and several cardiometabolic markers. Compounded tirzepatide at Telos Rx is not FDA-approved and is prescribed only after review by a licensed provider.
This reviews what the tirzepatide trials measured, in whom, and for how long. Weight results are covered elsewhere on this blog. What follows is the rest of the evidence base, including the open parts.
The First Approved Use Was Glucose, Not Weight
Tirzepatide is a dual GIP and GLP-1 receptor agonist made by Eli Lilly. Its first FDA approval came in 2022 under the brand Mounjaro, and that approval had nothing to do with weight management.
Per the Mounjaro prescribing information, the drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. That is the whole of the approved Mounjaro uses list.
People searching Mounjaro for weight loss are looking for the same molecule under a different label. Chronic weight management belongs to Zepbound, approved in November 2023, with obstructive sleep apnea in adults with obesity added in December 2024. Same drug, three approvals. The brand mapping is set out in Is Zepbound the same as tirzepatide? and Is Mounjaro tirzepatide?
What the SURPASS Trials Reported on Tirzepatide Glucose Control
SURPASS-2 is the trial that put tirzepatide glucose data next to a GLP-1 comparator. Adults with type 2 diabetes taking metformin were randomized to tirzepatide 5, 10 or 15 mg weekly, or to semaglutide 1 mg weekly, for 40 weeks.
At week 40 the label reports mean HbA1c reductions of 2.0, 2.2 and 2.3 percentage points for tirzepatide 5, 10 and 15 mg, against 1.9 percentage points for semaglutide 1 mg. Tirzepatide was noninferior and superior to semaglutide on that endpoint. Body weight fell further as well, with estimated treatment differences of 1.9 kg, 3.6 kg and 5.5 kg in favor of the three tirzepatide doses.
Those are averages in adults who already had type 2 diabetes. Incretin glucose-lowering is glucose-dependent, which is why hypoglycemia was uncommon in trials without insulin or a sulfonylurea. The molecule-level comparison sits in tirzepatide vs semaglutide.
Tirzepatide and Sleep Apnea: A Second Approved Indication
SURMOUNT-OSA was published in the New England Journal of Medicine in 2024 and led to the Zepbound sleep apnea indication. Two 52-week trials enrolled adults with moderate-to-severe obstructive sleep apnea and obesity, one group unable or unwilling to use positive airway pressure and one group already using it.
The published results reported apnea-hypopnea index reductions of 25.3 and 29.3 events per hour on tirzepatide, against 5.3 and 5.5 events per hour on placebo. Tirzepatide sleep apnea findings are covered in full, including who was excluded, in tirzepatide for sleep apnea research.
Trial data describes the people who were enrolled, not you. The way to find out whether tirzepatide is reasonable for your own history is a written intake read by a licensed provider.
See tirzepatide at Telos RxCardiometabolic Markers Measured Alongside Weight
Across the SURPASS program, blood pressure was tracked as a secondary measure. A pooled analysis in Cardiovascular Diabetology reported mean systolic reductions of 4.8, 5.8 and 7.0 mmHg at 40 weeks for the 5, 10 and 15 mg doses.
That analysis is honest about mechanism: the change was mediated primarily through weight loss, with a weak correlation between the two (r of roughly 0.18 to 0.22), which hints at a weight-independent contribution without isolating it. Hard cardiovascular endpoints are a separate question, handed off to tirzepatide cardiovascular outcomes research.
The Trial Map: Endpoints Other Than Body Weight
| Trial | Who was studied | What it measured | What it reported |
|---|---|---|---|
| SURPASS-2 | Adults with type 2 diabetes on metformin, 40 weeks | Change in HbA1c | 2.0 to 2.3 point reduction across doses, superior to semaglutide 1 mg |
| SURMOUNT-OSA | Adults with moderate-to-severe OSA and obesity, 52 weeks | Apnea-hypopnea index | 25.3 and 29.3 fewer events per hour vs 5.3 and 5.5 on placebo |
| SUMMIT | 731 adults with HFpEF and BMI of 30 or above, median 104 weeks | Cardiovascular death or worsening heart failure | Lower risk of the composite than placebo, plus improved health status scores |
| SURPASS-CVOT | 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease | Major adverse cardiovascular events | Noninferior to dulaglutide, hazard ratio 0.92, superiority not established |
A secondary analysis of SUMMIT in Nature Medicine put numbers on the intermediate markers at 52 weeks: systolic blood pressure 4.7 mmHg lower than placebo, estimated blood volume down by 0.58 liters, and C-reactive protein down by roughly 37 percent.
What the Trials Did Not Measure
This is the part most benefits-of-tirzepatide articles skip, and it changes how the numbers above should be read.
- None of these trials tested compounded tirzepatide. Every result on this page comes from Mounjaro or Zepbound at label doses. Compounded preparations were not the study drug.
- SURPASS-CVOT used an active comparator, not placebo. Tirzepatide was measured against dulaglutide, another GLP-1 receptor agonist. That answers "is it at least as good as an existing drug", not "how much better than nothing".
- SURMOUNT-OSA did not run tirzepatide head-to-head against airway pressure therapy. One trial enrolled people not using it and one enrolled people who stayed on it. Neither was designed to say tirzepatide can replace it.
- Durations were finite. Forty weeks, 52 weeks, a median of 104 weeks. Nothing here describes a decade of use.
- Enrollment criteria were narrow. Participants met specific diagnostic thresholds and were screened out for many conditions. Trial averages are not individual forecasts.
- Several endpoints were intermediate markers. HbA1c, apnea-hypopnea index, blood pressure and C-reactive protein are measurements, not events. Meaningful, but not the same as proven long-term outcomes.
The equivalent evidence review for the other molecule is semaglutide benefits beyond weight loss, where the cardiovascular question was studied against placebo and reached a different kind of answer.
How This Applies to Compounded Tirzepatide
Compounded tirzepatide is not FDA-approved. It is prepared by licensed US compounding pharmacies against a prescription written for an individual patient, and it has not been through the agency's own review of safety and effectiveness. The findings above describe branded products in trial conditions and should not be read as claims about a compounded preparation.
Tirzepatide carries a boxed warning for thyroid C-cell tumors observed in rodents, and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Gastrointestinal effects are the common ones, usually worst during titration, and are set out in tirzepatide side effects. Label titration starts at 2.5 mg weekly and rises in 2.5 mg steps no sooner than every four weeks, to a maximum of 15 mg. That is label information, not instruction.
Telos Rx is an online-first, asynchronous telehealth service and is LegitScript-certified. You complete a written intake, a licensed provider reviews it in writing and often responds within hours, and everything is subject to medical approval by a licensed provider. As of publication the tirzepatide page shows pricing as low as $139 per month, with flat pricing that does not rise as your dose is titrated, free 48-hour shipping if approved, FSA and HSA eligibility, and cancellation at any time. Lower starting doses are handled through microdosed tirzepatide.
Keep Reading
- What Is Tirzepatide? The Complete Guide
- Tirzepatide Benefits: Weight Management, Appetite and Metabolic Health
- Tirzepatide Dosage: The Titration Schedule Explained
- Tirzepatide Cost: Compounded vs Mounjaro and Zepbound
- How to Get Tirzepatide Online Safely: A Checklist
- Tirzepatide Pills: What Actually Exists
Frequently Asked Questions
What are the benefits of tirzepatide besides weight loss?
In trials, tirzepatide lowered HbA1c in adults with type 2 diabetes, reduced the apnea-hypopnea index in adults with obstructive sleep apnea and obesity, and lowered systolic blood pressure and C-reactive protein as secondary measures. Those are findings in studied populations, not promises. Compounded tirzepatide is not FDA-approved for any of them.
What is Mounjaro used for?
Mounjaro is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes. That is its only approved indication. Chronic weight management and obstructive sleep apnea are approved under Zepbound, which contains the same active molecule.
Does tirzepatide lower blood sugar in people without diabetes?
The glucose-lowering data comes from the SURPASS trials, which enrolled adults who already had type 2 diabetes. Incretin drugs act in a glucose-dependent way, which is why hypoglycemia was uncommon in trials without insulin or a sulfonylurea. What happens outside the studied population is a question for a licensed provider reviewing your history.
Is tirzepatide approved for sleep apnea?
Zepbound, the tirzepatide brand for weight management, received an FDA indication in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. That approval followed SURMOUNT-OSA. Mounjaro does not carry that indication, and compounded tirzepatide is not FDA-approved for sleep apnea or anything else.
Does tirzepatide lower blood pressure?
A pooled analysis of the SURPASS program reported mean systolic reductions of 4.8, 5.8 and 7.0 mmHg at 40 weeks across the 5, 10 and 15 mg doses. The authors concluded the effect was mediated primarily through weight loss. Blood pressure was a secondary measure, not the reason these trials were run.
Are compounded tirzepatide benefits the same as Mounjaro or Zepbound?
The published benefits were measured using the branded products at label doses. Compounded tirzepatide was not the study drug in any of these trials and is not FDA-approved, so trial results should not be transferred to it as claims. Whether a compounded preparation is appropriate is subject to evaluation by a licensed provider, and approval is not guaranteed.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
If the evidence above matches the question you came in with, the next step is a written evaluation. Start with the tirzepatide product page, then complete the intake here: start an online visit. A licensed provider reviews every request, and approval is not guaranteed.